Vir Biotechnology Inc (VIR)

$5.66 +0.07 (1.25%)
Market Cap 776.54M
Revenue (ttm) 74.21M
Net Income (ttm) -521.96M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin -703.36%
Debt to Equity Ratio 0.00
Volume 875,800
Avg Vol 1,314,082
Day's Range N/A - N/A
Shares Out 138.92M
Stochastic %K 60%
Beta 1.27
Analysts Strong Sell
Price Target $17.22

Company Profile

Vir Biotechnology, Inc., a clinical-stage biopharmaceutical company, discovers and develops therapeutic products to treat and prevent serious infectious diseases in the United States and internationally. Its clinical development pipeline consists of product investigational therapies targeting hepatitis delta virus (HDV) and other solid tumors.The company's preclinical candidates include those targeting influenza A and B, coronavirus disease 2019, respiratory syncytial virus (RSV) and human metap...

Industry: Biotechnology
Sector: Healthcare
Phone: 415 906 4324
Website: www.vir.bio
Address:
1800 Owens Street, Suite 900, San Francisco, United States
Dunnieboy1
Dunnieboy1 Oct. 7 at 10:40 PM
$VIR a subsidiary of Softbank sold over 500,000 shares recently, they still hold over 16m shares. No big worry as someone must of bought them.
0 · Reply
VIR_Tical1
VIR_Tical1 Oct. 7 at 1:53 PM
$VIR “Vir Biotechnology to Present Week 48 SOLSTICE Clinical Results in Hepatitis Delta at AASLD’s The Liver Meeting® 2025 – Week 48 endpoint results from the SOLSTICE Phase 2 clinical study evaluating tobevibart alone or in combination with elebsiran for chronic hepatitis delta to be presented – Vir Biotechnology to showcase progress in hepatitis delta clinical efforts with one oral and one poster presentation.” See Prior Link for more info:
1 · Reply
VIR_Tical1
VIR_Tical1 Oct. 7 at 1:14 PM
$VIR https://investors.vir.bio/news/news-details/2025/Vir-Biotechnology-to-Present-Week-48-SOLSTICE-Clinical-Results-in-Hepatitis-Delta-at-AASLDs-The-Liver-Meeting-2025/default.aspx
0 · Reply
newTrader9999
newTrader9999 Oct. 7 at 1:07 PM
$VIR pathetic stock . White collar criminal management. No wonder people short biotechs. Organized fraud
0 · Reply
Dunnieboy1
Dunnieboy1 Oct. 5 at 8:20 AM
$VIR Sato sold stock which represents 1.75% of her holding, new kitchen? Director Vicki Sato sold 22,000 shares of Vir Biotechnology at an average price of $5.84, totaling $128,480, which represents a 1.75% decrease in her stock position.
0 · Reply
btwtrading8382
btwtrading8382 Oct. 3 at 1:51 PM
$VIR any news?
0 · Reply
Dunnieboy1
Dunnieboy1 Oct. 2 at 5:50 PM
$VIR
1 · Reply
Jhawkin
Jhawkin Oct. 2 at 1:28 PM
$VIR what’s our next hype date or milestone to look for? Seems a bit too quiet with no news recently.
1 · Reply
Mhand
Mhand Oct. 1 at 8:04 PM
$VIR What a kick in the balls today's action was. Heavy manipulation again.
0 · Reply
Dunnieboy1
Dunnieboy1 Oct. 1 at 1:43 PM
$VIR like a phoenix from the flames😂
1 · Reply
Latest News on VIR
Vir Biotechnology to Present Week 48 SOLSTICE Clinical Results in Hepatitis Delta at AASLD's The Liver Meeting® 2025

Oct 7, 2025, 8:00 AM EDT - 20 hours ago

Vir Biotechnology to Present Week 48 SOLSTICE Clinical Results in Hepatitis Delta at AASLD's The Liver Meeting® 2025

Vir Biotechnology, Inc. (VIR) Presents At Morgan Stanley 23rd Annual Global Healthcare Conference Transcript

Sep 16, 2025, 1:15 PM EDT - 21 days ago

Vir Biotechnology, Inc. (VIR) Presents At Morgan Stanley 23rd Annual Global Healthcare Conference Transcript

Vir Biotechnology to Participate in the Morgan Stanley 23rd Annual Global Healthcare Conference

Aug 25, 2025, 4:05 PM EDT - 6 weeks ago

Vir Biotechnology to Participate in the Morgan Stanley 23rd Annual Global Healthcare Conference

Vir Biotechnology, Inc. (VIR) Q2 2025 Earnings Call Transcript

Aug 6, 2025, 11:01 PM EDT - 2 months ago

Vir Biotechnology, Inc. (VIR) Q2 2025 Earnings Call Transcript

Vir Biotechnology Provides Corporate Update and Reports Second Quarter 2025 Financial Results

Aug 6, 2025, 4:05 PM EDT - 2 months ago

Vir Biotechnology Provides Corporate Update and Reports Second Quarter 2025 Financial Results

Vir Biotechnology Successfully Initiates all Trials in ECLIPSE Registrational Program for Chronic Hepatitis Delta

Aug 6, 2025, 8:05 AM EDT - 2 months ago

Vir Biotechnology Successfully Initiates all Trials in ECLIPSE Registrational Program for Chronic Hepatitis Delta

Vir Biotechnology Initiates Second Pivotal Trial in Its Global ECLIPSE Registrational Program for Chronic Hepatitis Delta

Jul 31, 2025, 8:05 AM EDT - 2 months ago

Vir Biotechnology Initiates Second Pivotal Trial in Its Global ECLIPSE Registrational Program for Chronic Hepatitis Delta

Vir Biotechnology Announces First Patient Dosed in Phase 1 Clinical Trial of EGFR-Targeting PRO-XTEN™ Dual-Masked T-Cell Engager VIR-5525 for the Treatment of Solid Tumors

Jul 24, 2025, 8:05 AM EDT - 2 months ago

Vir Biotechnology Announces First Patient Dosed in Phase 1 Clinical Trial of EGFR-Targeting PRO-XTEN™ Dual-Masked T-Cell Engager VIR-5525 for the Treatment of Solid Tumors

Vir Biotechnology: Hep B And Cancer Projects March On

Jul 23, 2025, 12:10 PM EDT - 2 months ago

Vir Biotechnology: Hep B And Cancer Projects March On

Vir Biotechnology to Provide Corporate Update and Report Second Quarter 2025 Financial Results on August 6, 2025

Jul 22, 2025, 4:05 PM EDT - 2 months ago

Vir Biotechnology to Provide Corporate Update and Report Second Quarter 2025 Financial Results on August 6, 2025

20 stocks you should avoid — no matter how well the market does

Jun 11, 2025, 7:00 AM EDT - 4 months ago

20 stocks you should avoid — no matter how well the market does

CORT CPRX CRK CRNC DDD LUMN LYV

Vir Biotechnology to Participate in the Goldman Sachs 46th Annual Global Healthcare Conference 2025

May 28, 2025, 4:05 PM EDT - 4 months ago

Vir Biotechnology to Participate in the Goldman Sachs 46th Annual Global Healthcare Conference 2025

Vir Biotechnology to Participate in TD Cowen 6th Annual Oncology Innovation Summit

May 20, 2025, 4:05 PM EDT - 5 months ago

Vir Biotechnology to Participate in TD Cowen 6th Annual Oncology Innovation Summit

Vir Biotechnology to Participate in Bank of America Securities 2025 Healthcare Conference

May 12, 2025, 4:05 PM EDT - 5 months ago

Vir Biotechnology to Participate in Bank of America Securities 2025 Healthcare Conference

Vir Biotechnology Announces Preliminary 24-Week Post-End of Treatment Data for Tobevibart and Elebsiran Combinations in Chronic Hepatitis B From the MARCH Study

May 9, 2025, 6:00 AM EDT - 5 months ago

Vir Biotechnology Announces Preliminary 24-Week Post-End of Treatment Data for Tobevibart and Elebsiran Combinations in Chronic Hepatitis B From the MARCH Study

Vir Biotechnology: Tobevibart Combination Pushing Forward For Needed HDV Treatment

May 8, 2025, 3:37 PM EDT - 5 months ago

Vir Biotechnology: Tobevibart Combination Pushing Forward For Needed HDV Treatment

Vir Biotechnology, Inc. (VIR) Q1 2025 Earnings Call Transcript

May 7, 2025, 11:21 PM EDT - 5 months ago

Vir Biotechnology, Inc. (VIR) Q1 2025 Earnings Call Transcript

Vir Biotechnology Provides Corporate Update and Reports First Quarter 2025 Financial Results

May 7, 2025, 4:05 PM EDT - 5 months ago

Vir Biotechnology Provides Corporate Update and Reports First Quarter 2025 Financial Results

Vir Biotechnology to Provide Corporate Update and Report First Quarter 2025 Financial Results on May 7, 2025

Apr 30, 2025, 4:05 PM EDT - 5 months ago

Vir Biotechnology to Provide Corporate Update and Report First Quarter 2025 Financial Results on May 7, 2025

Vir Biotechnology to Present Latest Clinical Data in Hepatitis Delta and B Programs at the European Association for the Study of the Liver (EASL) Congress 2025

Apr 24, 2025, 9:30 AM EDT - 5 months ago

Vir Biotechnology to Present Latest Clinical Data in Hepatitis Delta and B Programs at the European Association for the Study of the Liver (EASL) Congress 2025

Brii Biosciences Provides Corporate Update and Reports Full-Year 2024 Financial Results

Mar 21, 2025, 7:10 AM EDT - 7 months ago

Brii Biosciences Provides Corporate Update and Reports Full-Year 2024 Financial Results

Vir Biotechnology Enrolls First Patient in Phase 3 ECLIPSE Registrational Program for Chronic Hepatitis Delta

Mar 13, 2025, 8:05 AM EDT - 7 months ago

Vir Biotechnology Enrolls First Patient in Phase 3 ECLIPSE Registrational Program for Chronic Hepatitis Delta

Vir Biotechnology, Inc. (VIR) Q4 2024 Earnings Call Transcript

Feb 26, 2025, 11:22 PM EST - 7 months ago

Vir Biotechnology, Inc. (VIR) Q4 2024 Earnings Call Transcript

Vir Biotechnology Provides Corporate Update and Reports Fourth Quarter and Full Year 2024 Financial Results

Feb 26, 2025, 4:05 PM EST - 7 months ago

Vir Biotechnology Provides Corporate Update and Reports Fourth Quarter and Full Year 2024 Financial Results

Vir Biotechnology to Participate in TD Cowen 45th Annual Health Care Conference

Feb 19, 2025, 4:05 PM EST - 8 months ago

Vir Biotechnology to Participate in TD Cowen 45th Annual Health Care Conference

Vir Biotechnology to Provide Corporate Update and Report Fourth Quarter and Full Year 2024 Financial Results on February 26, 2025

Feb 12, 2025, 4:05 PM EST - 8 months ago

Vir Biotechnology to Provide Corporate Update and Report Fourth Quarter and Full Year 2024 Financial Results on February 26, 2025

Top 5 Cancer Pharma Stocks With Strong Risk/Reward In 2025

Jan 13, 2025, 6:10 PM EST - 9 months ago

Top 5 Cancer Pharma Stocks With Strong Risk/Reward In 2025

ABBV AMGN AZN BNTX FBCG GILD GSK

Morgan Stanley Doubles Vir Biotechnology Price Forecast - Here's Why

Jan 10, 2025, 2:32 PM EST - 9 months ago

Morgan Stanley Doubles Vir Biotechnology Price Forecast - Here's Why

Vir Biotechnology: A Rocket Off Phase 1 Data

Jan 9, 2025, 9:00 AM EST - 9 months ago

Vir Biotechnology: A Rocket Off Phase 1 Data

Vir Biotechnology Stock Soars On Prostate Cancer Trial Data - Here's Why

Jan 8, 2025, 12:28 PM EST - 9 months ago

Vir Biotechnology Stock Soars On Prostate Cancer Trial Data - Here's Why

Vir Biotechnology Announces Encouraging Safety and Efficacy Data in Ongoing Dose Escalation Trials for Dual Masked T-Cell Engagers VIR-5818 in Solid Tumors and VIR-5500 in mCRPC

Jan 8, 2025, 7:45 AM EST - 9 months ago

Vir Biotechnology Announces Encouraging Safety and Efficacy Data in Ongoing Dose Escalation Trials for Dual Masked T-Cell Engagers VIR-5818 in Solid Tumors and VIR-5500 in mCRPC

Vir Biotechnology to Present at the 43rd Annual J.P. Morgan Healthcare Conference

Dec 18, 2024, 9:30 AM EST - 10 months ago

Vir Biotechnology to Present at the 43rd Annual J.P. Morgan Healthcare Conference

Vir Biotechnology Could Be An Early Riser In 2025 With Oncology Data In January

Dec 13, 2024, 12:57 PM EST - 10 months ago

Vir Biotechnology Could Be An Early Riser In 2025 With Oncology Data In January

Vir Biotechnology Receives FDA Breakthrough Therapy Designation and EMA PRIME Designation for Tobevibart and Elebsiran in Chronic Hepatitis Delta

Dec 12, 2024, 4:05 PM EST - 10 months ago

Vir Biotechnology Receives FDA Breakthrough Therapy Designation and EMA PRIME Designation for Tobevibart and Elebsiran in Chronic Hepatitis Delta

Vir Biotechnology to Host Virtual Investor Event on PRO-XTEN™ Masked T-Cell Engager Programs

Nov 26, 2024, 9:30 AM EST - 11 months ago

Vir Biotechnology to Host Virtual Investor Event on PRO-XTEN™ Masked T-Cell Engager Programs

Vir Biotechnology to Participate in the 7th Annual Evercore ISI HealthCONx Conference

Nov 25, 2024, 9:30 AM EST - 11 months ago

Vir Biotechnology to Participate in the 7th Annual Evercore ISI HealthCONx Conference

Vir Biotechnology Presents Positive Chronic Hepatitis Delta Clinical Trial Data and Announces Initiation of Phase 3 Registrational Program

Nov 18, 2024, 9:15 PM EST - 11 months ago

Vir Biotechnology Presents Positive Chronic Hepatitis Delta Clinical Trial Data and Announces Initiation of Phase 3 Registrational Program

Vir Biotechnology Receives Positive Opinion on Orphan Drug Designation for Tobevibart and Elebsiran in Chronic Hepatitis Delta from European Medicines Agency

Nov 18, 2024, 4:05 PM EST - 11 months ago

Vir Biotechnology Receives Positive Opinion on Orphan Drug Designation for Tobevibart and Elebsiran in Chronic Hepatitis Delta from European Medicines Agency

Vir Biotechnology Announces Positive End-of-Treatment Results for Tobevibart and Elebsiran Combinations in Chronic Hepatitis B from the MARCH Study at AASLD The Liver Meeting

Nov 15, 2024, 11:00 AM EST - 11 months ago

Vir Biotechnology Announces Positive End-of-Treatment Results for Tobevibart and Elebsiran Combinations in Chronic Hepatitis B from the MARCH Study at AASLD The Liver Meeting

Vir Biotechnology's Refocused Pipeline: Hepatitis And Oncology Could Still Pay Off

Nov 5, 2024, 11:29 AM EST - 1 year ago

Vir Biotechnology's Refocused Pipeline: Hepatitis And Oncology Could Still Pay Off

Vir Biotechnology, Inc. (VIR) Q3 2024 Earnings Call Transcript

Oct 31, 2024, 11:12 PM EDT - 1 year ago

Vir Biotechnology, Inc. (VIR) Q3 2024 Earnings Call Transcript

Vir Biotechnology Reports Third Quarter 2024 Financial Results and Provides Corporate Update

Oct 31, 2024, 4:05 PM EDT - 1 year ago

Vir Biotechnology Reports Third Quarter 2024 Financial Results and Provides Corporate Update

Vir Biotechnology to Provide Business Update and Report Third Quarter 2024 Financial Results on October 31, 2024

Oct 17, 2024, 4:30 PM EDT - 1 year ago

Vir Biotechnology to Provide Business Update and Report Third Quarter 2024 Financial Results on October 31, 2024

Vir Biotechnology Announces Clinical Advances Across Hepatitis Delta and Hepatitis B Programs at AASLD's The Liver Meeting® 2024

Oct 15, 2024, 8:16 AM EDT - 1 year ago

Vir Biotechnology Announces Clinical Advances Across Hepatitis Delta and Hepatitis B Programs at AASLD's The Liver Meeting® 2024

Vir Biotechnology to Participate in the H.C. Wainwright 5th Annual Viral Hepatitis Virtual Conference

Oct 3, 2024, 4:00 PM EDT - 1 year ago

Vir Biotechnology to Participate in the H.C. Wainwright 5th Annual Viral Hepatitis Virtual Conference

Vir Biotechnology Appoints Jason O'Byrne as Chief Financial Officer

Sep 10, 2024, 8:05 AM EDT - 1 year ago

Vir Biotechnology Appoints Jason O'Byrne as Chief Financial Officer

Vir Biotechnology Announces Closing of Exclusive Worldwide License Agreement With Sanofi for Multiple Potential Best-in-Class Clinical-Stage T-Cell Engagers

Sep 9, 2024, 4:05 PM EDT - 1 year ago

Vir Biotechnology Announces Closing of Exclusive Worldwide License Agreement With Sanofi for Multiple Potential Best-in-Class Clinical-Stage T-Cell Engagers

Vir Biotechnology to Participate in the Morgan Stanley 22nd Annual Global Healthcare Conference

Aug 22, 2024, 8:05 AM EDT - 1 year ago

Vir Biotechnology to Participate in the Morgan Stanley 22nd Annual Global Healthcare Conference

Vir Biotechnology, Inc. (VIR) Q2 2024 Earnings Call Transcript

Aug 1, 2024, 10:10 PM EDT - 1 year ago

Vir Biotechnology, Inc. (VIR) Q2 2024 Earnings Call Transcript

Vir Biotechnology Reports Second Quarter 2024 Financial Results and Announces Strategic Restructuring to Prioritize Clinical-Stage Pipeline Opportunities

Aug 1, 2024, 4:02 PM EDT - 1 year ago

Vir Biotechnology Reports Second Quarter 2024 Financial Results and Announces Strategic Restructuring to Prioritize Clinical-Stage Pipeline Opportunities

Dunnieboy1
Dunnieboy1 Oct. 7 at 10:40 PM
$VIR a subsidiary of Softbank sold over 500,000 shares recently, they still hold over 16m shares. No big worry as someone must of bought them.
0 · Reply
VIR_Tical1
VIR_Tical1 Oct. 7 at 1:53 PM
$VIR “Vir Biotechnology to Present Week 48 SOLSTICE Clinical Results in Hepatitis Delta at AASLD’s The Liver Meeting® 2025 – Week 48 endpoint results from the SOLSTICE Phase 2 clinical study evaluating tobevibart alone or in combination with elebsiran for chronic hepatitis delta to be presented – Vir Biotechnology to showcase progress in hepatitis delta clinical efforts with one oral and one poster presentation.” See Prior Link for more info:
1 · Reply
VIR_Tical1
VIR_Tical1 Oct. 7 at 1:14 PM
$VIR https://investors.vir.bio/news/news-details/2025/Vir-Biotechnology-to-Present-Week-48-SOLSTICE-Clinical-Results-in-Hepatitis-Delta-at-AASLDs-The-Liver-Meeting-2025/default.aspx
0 · Reply
newTrader9999
newTrader9999 Oct. 7 at 1:07 PM
$VIR pathetic stock . White collar criminal management. No wonder people short biotechs. Organized fraud
0 · Reply
Dunnieboy1
Dunnieboy1 Oct. 5 at 8:20 AM
$VIR Sato sold stock which represents 1.75% of her holding, new kitchen? Director Vicki Sato sold 22,000 shares of Vir Biotechnology at an average price of $5.84, totaling $128,480, which represents a 1.75% decrease in her stock position.
0 · Reply
btwtrading8382
btwtrading8382 Oct. 3 at 1:51 PM
$VIR any news?
0 · Reply
Dunnieboy1
Dunnieboy1 Oct. 2 at 5:50 PM
$VIR
1 · Reply
Jhawkin
Jhawkin Oct. 2 at 1:28 PM
$VIR what’s our next hype date or milestone to look for? Seems a bit too quiet with no news recently.
1 · Reply
Mhand
Mhand Oct. 1 at 8:04 PM
$VIR What a kick in the balls today's action was. Heavy manipulation again.
0 · Reply
Dunnieboy1
Dunnieboy1 Oct. 1 at 1:43 PM
$VIR like a phoenix from the flames😂
1 · Reply
Dunnieboy1
Dunnieboy1 Sep. 29 at 4:33 PM
$VIR are we in recovery mode?
0 · Reply
Dunnieboy1
Dunnieboy1 Sep. 27 at 11:20 AM
$VIR actually finished up 25.06% on the month, imagine the sp compounding at 25.06 per month, we’d all be rich in no time😂
0 · Reply
Dunnieboy1
Dunnieboy1 Sep. 26 at 6:09 PM
$VIR up 22% mtd, nice rise albeit off a very low base.
0 · Reply
Dunnieboy1
Dunnieboy1 Sep. 23 at 1:59 PM
$VIR it appears we’re in good hands; We’re proud to share that The Healthcare Technology Report has named our Chief Executive Officer Marianne De Backer, MSc, PhD, MBA, as one of its Top 25 Biotech and Life Sciences Executives of 2025.
2 · Reply
Dunnieboy1
Dunnieboy1 Sep. 22 at 3:34 PM
$VIR up over 5% so far, that’s on the back of thursdays rise of over 7%(Friday we stayed level with thursday).
1 · Reply
Dunnieboy1
Dunnieboy1 Sep. 18 at 7:11 PM
$VIR nice steady rise today
0 · Reply
Dunnieboy1
Dunnieboy1 Sep. 17 at 10:05 AM
$VIR Vir Biotechnology, the Healthcare sector company, was revisited by a Wall Street analyst today. Analyst from H.C. Wainwright reiterated a Buy rating on the stock and has a $15.00 price target.
0 · Reply
justme_DC
justme_DC Sep. 15 at 6:30 PM
$VIR Ugly price action today. But interesting (yes, I know just one small piece of many) is the nice inflow vs. outflow and that 17 DTC on Fintel. Time will tell, could be a nice set up.
0 · Reply
Njdude
Njdude Sep. 12 at 7:10 PM
$VIR I just realized that we got fast track designation in June of 2024 so we are in our 15 month already. Google search said it takes 1 to 3 years for phase 3 trials but I couldn’t find anything on how long it takes with fast track. Either way we are almost half way to 3 years. Let’s hope for some good news soon.
0 · Reply
Dunnieboy1
Dunnieboy1 Sep. 10 at 4:19 PM
$VIR we are actually up month to date by 20%, it would be nice to recover at 20% a month, imagine the effect of compounding at that rate.
0 · Reply
Njdude
Njdude Sep. 10 at 12:13 AM
$VIR anyone know how the fireside chat went today ?
2 · Reply
Dunnieboy1
Dunnieboy1 Sep. 8 at 10:41 AM
$VIR let’s smash $6 this week, we are definitely trying to build at the moment. I read yesterday about meme stocks such as Gamestore are starting to shoot up again, basically Reddit identifies stocks which are heavily shorted and advises it’s members to start buying & then the shorters have to close their positions creating massive bounces of up to 1200%. It happened to Vir years ago when the Reddit brigade & Robin Hood started buying up our shares & in minutes our price went up to $140 before quickly settling back, lets hope history repeats itself.
1 · Reply